Bremelanotide for HSDD in Premenopausal Women: RECONNECT Trials
Obstetrics & Gynecology (2019)
Significantly improved sexual desire and reduced distress vs placebo in two Phase III trials (n=1,247).
Bremelanotide (PT-141)
Nasal spray (10mg/mL), Injectable (10mg/mL vial), Troche (0.25 to 2mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
sexual health
Bremelanotide (PT-141)Bremelanotide (PT-141)
Melanocortin-4 receptor (MC4R) agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on sexual desire pathways rather than peripheral vascular mechanisms, representing a fundamentally different approach from PDE5 inhibitors.
Acts on central desire pathways, addresses libido, not just erection
FDA-approved with Phase III evidence
On-demand dosing (45 min before activity)
Effective in both men and women
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Activates MC4R in the hypothalamus and limbic system, modulating dopaminergic and oxytocinergic pathways involved in sexual desire and arousal. Unlike PDE5i, acts on central desire circuits rather than peripheral blood flow.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Bremelanotide (PT-141).
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Nausea (40%, most common, dose-limiting)
- Flushing
- Injection site reactions
- Headache
- Transient hypertension
Less common but serious risks
- Blood pressure elevation (contraindicated in uncontrolled HTN)
- Nausea can be severe
- Potential melanocyte stimulation (skin darkening, focal hyperpigmentation)
Generally not appropriate for
- Uncontrolled hypertension
- Known cardiovascular disease
- Pregnancy
Typical monitoring
- Blood pressure before and after use
- Skin exam (hyperpigmentation)
- Sexual function scores
FAQ
Quick answers.
Melanocortin-4 receptor (MC4R) agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on sexual desire pathways rather than peripheral vascular mechanisms, representing a fundamentally different approach from PDE5 inhibitors.
Acts on central desire pathways, addresses libido, not just erection. FDA-approved with Phase III evidence. On-demand dosing (45 min before activity). Effective in both men and women.
Common side effects include: nausea (40%, most common, dose-limiting), flushing, injection site reactions, headache, transient hypertension. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Melanocortin-4 receptor (MC4R) agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on sexual desire pathways rather than peripheral vascular mechanisms, representing a fundamentally different approach from PDE5 inhibitors.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.